Abciximab in acute ischemic stroke : A randomized, double-blind, placebo-controlled, dose-escalation study

Abciximab is a potent parenterally administered platelet glycoprotein IIb/IIIa antagonist. Because this agent has been shown to improve outcomes in coronary artery disease, there is interest to evaluate whether it could improve cerebral perfusion and outcomes after ischemic stroke. This study was de...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2000-03, Vol.31 (3), p.601-609
1. Verfasser:	Investigators, The Abciximab in Ischemic Stroke
Format:	Artikel
Sprache:	eng
Schlagworte:	Abciximab Acute Disease Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Brain Ischemia - diagnostic imaging Brain Ischemia - drug therapy Dose-Response Relationship, Drug Double-Blind Method Female Humans Immunoglobulin Fab Fragments - administration & dosage Immunoglobulin Fab Fragments - adverse effects Immunoglobulin Fab Fragments - therapeutic use Length of Stay Male Medical sciences Middle Aged Neurology Pharmacology. Drug treatments Placebos Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Radiography Safety Stroke - diagnostic imaging Stroke - drug therapy Stroke - mortality Treatment Outcome Vascular diseases and vascular malformations of the nervous system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!